Ergocalciferol and cholecalciferol in CKD

American Journal of Kidney Diseases

Volumn 60, Issue 1, 2012, Pages 139-156

  Nigwekar, Sagar U ^a,b   Bhan, Ishir ^a   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cholecalciferol; chronic kidney disease; end stage renal disease; ergocalciferol; vitamin D

Indexed keywords

COLECALCIFEROL; ERGOCALCIFEROL;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

AGED; CALCIFEDIOL; CHOLECALCIFEROL; ERGOCALCIFEROLS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84862610390     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.12.035     Document Type: Article

References (174)

1. US National Academy of Sciences. Unraveling the enigma of vitamin D. http://www.beyonddiscovery.org. Accessed June 30, 2011.
2. Hess AF. The prevention and cure of rickets by sunlight. Am J Public Health (N Y). 1922;12(2):104-107.
3. The Nobel Foundation. Adolf Windaus-biography. http://www.nobelprize.org. Accessed June 30, 2011.
4. Askew FA, Bourdillon RB, Bruce HM, Jenkins RGC, Webster TA. The distillation of vitamin D. Proceedings of the Royal Society. 1931;B107:76-90.
5. Lawson DE, Fraser DR, Kodicek E, Morris HR, Williams DH. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature. 1971;230(5291):228-230.
6. Fraser DR, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970;228(5273):764-766.
7. Mawer EB, Taylor CM, Backhouse J, Lumb GA, Stanbury SW. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet. 1973;1(7804):626-628.
8. Brown AJ. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J Steroid Biochem Mol Biol. 2007;103(3-5):578-583.
9. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground: chronic kidney disorders mineral and bone disease - calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol. 2008;3(1):168-173.
10. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol. 2009;5(1):24-33.
11. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446-456.
12. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115-1125.
13. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004-1013.
14. 3. Cancer Epidemiol Biomarkers Prev. 1998;7(5):391-395.
15. Brown AJ. Therapeutic uses of vitamin D analogues. Am J Kidney Dis. 2001;38(5)(suppl 5):S3-S19.
16. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8-F28.
17. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770- 1773.
18. 3 by interferon-gamma-stimulated normal human bone marrow and alveolar macrophages. J Biol Chem. 1987;262(23):10931-10937.
19. Holick MF. Vitamin D: a D-lightful health perspective. Nutr Rev. 2008;66(10)(suppl 2):S182-S194.
20. 3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103(3-5):316-321.
21. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-2072.
22. Zehnder D, Bland R,Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888-894.
23. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147(12):840-853.
24. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(9):1529-1539.
25. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45(6):1026-1033.
26. Bhan I, Burnett-Bowie SA, Ye J, Tonelli M, Thadhani R. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol. 2010;5(3):460-467.
27. Ishimura E, Nishizawa Y, Inaba M, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55(3):1019-1027.
28. National Kidney Founation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(4)(suppl 3):S1-S201.
29. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-S130.
30. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6(1):50-62.
31. Vieth R. Why "vitamin D" is not a hormone, and not a synonym for 1,25-dihydroxy-vitamin D, its analogs or deltanoids. J Steroid Biochem Mol Biol. 2004;89-90(1-5):571-573.
32. Vitamin D. http://pubchem.ncbi.nlm.nih.gov/. Accessed December 30, 2011.
33. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
34. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28.
35. Feldman D. Vitamin D. Vol 1. ed 3.Waltham, MA: Elsevier; 2011.
36. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135(2):317-322.
37. Khosla S. What do we tell our patients about calcium and vitamin D supplementation? J Clin Endocrinol Metab. 2011;96(1):69-71.
38. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc. 2011;86(1):50-60.
39. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5):439-443.
40. Bhan I, Hewison M, Thadhani R. Dietary vitamin D intake in advanced CKD/ESRD. Semin Dial. 2010;23(4):407-410.
41. Haddad JG. Vitamin D - solar rays, the Milky Way, or both? N Engl J Med. 1992;326(18):1213-1215.
42. Stamp TC, Haddad JG, Twigg CA. Comparison of oral 25- hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. Lancet. 1977;1(8026):1341-1343.
43. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr. 1984;114(7):1313-1319.
44. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982;1(8263):74-76.
45. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447-E452.
46. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101(20):7711-7715.
47. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. Endocrinol Metab Clin North Am. 2010;39(2):243-253, table of contents.
48. 3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest. 1984;74(4):1540-1544.
49. 3metabolites. Biochem Biophys Res Commun. 2006;345(2):568-572.
50. Hollis BW. Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am. 2010;39(2):271-286, table of contents.
51. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986;63(4):954-959.
52. 3 metabolism. Kidney Int. 2002;62(5):1672-1681.
53. Willnow TE, Nykjaer A. Pathways for kidney-specific uptake of the steroid hormone 25-hydroxyvitamin D3. Curr Opin Lipidol. 2002;13(3):255-260.
54. 3. Cell. 1999;96(4):507-515.
55. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science. 1997;277(5333):1827-1830.
56. Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol. 2000;25(2):141-148.
57. 3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol. 1999;10(12):2465-2473.
58. Qazi RA, Martin KJ. Vitamin D in kidney disease: pathophysiology and the utility of treatment. Endocrinol Metab Clin North Am. 2010;39(2):355-363, table of contents.
59. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6)(suppl):1689S-1696S.
60. 3 metabolically active in the intestine. Proc Natl Acad Sci U S A. 1971;68(4):803-804.
61. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and bone. J Cell Biochem. 2003;88(2):259-266.
62. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr. 2004;80(3):752-758.
63. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-238.
64. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307-314.
65. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205(1):255-260.
66. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726-776.
67. Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2010;39(2):419-446, table of contents.
68. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006;103(18):7048-7053.
69. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009;169(4):384-390.
70. Ponsonby AL, McMichael A, van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology. 2002;181-182:71-78.
71. 3, and the immune system. Am J Clin Nutr. 2004;80(6)(suppl):1717S-1720S.
72. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med. 2011;3(104):1-10.
73. Fernandes de Abreu DA, Eyles D, Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009;34(suppl 1):S265-S277.
74. Eyles DW, Feron F, Cui X, et al. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology. 2009;34(suppl 1):S247-S257.
75. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662-687.
76. Holick MF. Vitamin D: a d-lightful solution for health. J Investig Med. 2011;59(6):872-880.
77. Prie D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol. 2010;5(9):1717-1722.
78. 3) 24-hydroxylase gene. Proc Natl Acad Sci U S A. 1994;91(3):900-902.
79. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant. 1991;6(3):162-169.
80. Rickers H, Christiansen C, Christensen P, Christensen M, Rodbro P. Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron. 1985;39(3):267-271.
81. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503-510.
82. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58(3):374-382.
83. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38.
84. Mehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):1144-1151.
85. Jean G, Lataillade D, Genet L, et al. Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS Study. Nephron Clin Pract. 2011;118(2):c204-c210.
86. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315-321.
87. Hu P, Hu B, Wang J, Lu L, Qin YH. Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease. Med Sci Monit. 2011;17(6):HY14-HY20.
88. Holick MF. Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. Fed Proc. 1987;46(5):1876-1882.
89. Abdelbaqi-Salhab M, Shalhub S, Morgan MB. A current review of the cutaneous manifestations of renal disease. J Cutan Pathol. 2003;30(9):527-538.
90. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial. 2005;18(4):315-321.
91. Cuppari L, Garcia Lopes MG, Kamimura MA. Vitamin D biology: from the discovery to its significance in chronic kidney disease. J Ren Nutr. 2011;21(1):113-116.
92. Cuppari L, Garcia-Lopes MG. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment. J Ren Nutr. 2009;19(1):38-43.
93. 3 in azotemic rats. Am J Clin Nutr. 1983;37(3):403-406.
94. 3in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol. 2006;38(2):323-329.
95. Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med. 1982;99(3):325-330.
96. Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int. 1992;41(1):161-165.
97. Joffe P, Heaf JG. Vitamin D and vitamin-D-binding protein kinetics in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int. 1989;9(4):281-284.
98. Rapoport J, Shany S, Chaimovitz C. Continuous ambulatory peritoneal dialysis and vitamin D. Nephron. 1988;48(1):1-3.
99. Shany S, Rapoport J, Goligorsky M, Yankowitz N, Zuili I, Chaimovitz C. Losses of 1,25- and 24,25-dihydroxycholecalciferol in the peritoneal fluid of patients treated with continuous ambulatory peritoneal dialysis. Nephron. 1984;36(2):111-113.
100. 3. J Clin Endocrinol Metab. 1984;59(6):1063-1069.
101. 3 or 1,25-dihydroxycholecalciferol. Lancet. 1980;2(8195, pt 1):612-615.
102. 3 in intact animals. Endocrinology. 1999;140(5):2224-2231.
103. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int. 2010;78(2):134-139.
104. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):2600-2608.
105. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-435.
106. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205-2215.
107. Lu KC, Lin SH, Yu FC, Chyr SH, Shieh SD. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure. Miner Electrolyte Metab. 1995;21(6):398-402.
108. Kawashima H, Kraut JA, Kurokawa K. Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action. J Clin Invest. 1982;70(1):135-140.
109. Hsu CH, Vanholder R, Patel S, De Smet RR, Sandra P, Ringoir SM. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int. 1991;40(5):868-873.
110. 2D in renal failure. J Am Soc Nephrol. 1993;4(4):1035-1038.
111. 3 in patients with gout. Metabolism. 1998;47(3):336-338.
112. Nykjaer A, Fyfe JC, Kozyraki R, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A. 2001;98(24):13895-13900.
113. Kaseda R, Hosojima M, Sato H, Saito A. Role of megalin and cubilin in the metabolism of vitamin D(3). Ther Apher Dial. 2011;15(suppl 1):14-17.
114. Takemoto F, Shinki T, Yokoyama K, et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int. 2003;64(2):414-420.
115. Dusso AS, Finch J, Brown A, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab. 1991;72(1):157-164.
116. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92(3):1436-1443.
117. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest. 1995;96(1):50-59.
118. Hsu CH, Patel SR. Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: calcitriol receptor interaction with its target gene in renal failure. Curr Opin Nephrol Hypertens. 1995;4(4):302-306.
119. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28(5):1228-1230.
120. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28(12):2926-2932.
121. Petchey WG, Johnson DW, Isbel NM. Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton). 2011;16(4):351-367.
122. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes.Asystematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017-2029.
123. Voors AW, Johnson WD. Altitude and arteriosclerotic heart disease mortality in white residents of 99 of the 100 largest cities in the United States. J Chronic Dis. 1979;32(1-2):157-162.
124. Semba RD, Houston DK, Bandinelli S, et al. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur J Clin Nutr. 2010;64(2):203-209.
125. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174-1180.
126. Pilz S, Dobnig H, Fischer JE, et al. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke. 2008;39(9):2611-2613.
127. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349.
128. Melamed ML, Michos ED, PostW, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629-1637.
129. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-511.
130. The Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. www.iom.edu. Accessed July 30, 2011.
131. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med. 2002;112(8):659-662.
132. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2002;76(1):187-192.
133. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12): 777-783.
134. Figuiredo-Dias V, Cuppari L, Garcia-Lopes MG, de Carvalho AB, Draibe SA, Kamimura MA. Risk factors for hypovitaminosis D in nondialyzed chronic kidney disease patients. J Ren Nutr. 2012;22(1):4-11.
135. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1128-1135.
136. Stefikova K, Spustova V, Krivosikova Z, et al. Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. Physiol Res. 2011;60(1):149-155.
137. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007;50(1):69-77.
138. Diaz VA, Mainous AG III, Carek PJ, Wessell AM, Everett CJ. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Family Med. 2009;22(5):521-527.
139. Isakova T, Gutierrez OM, Patel NM, Andress DL,Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr. 2011;21(4):295-302.
140. Fiscella KA, Winters PC, Ogedegbe G. Vitamin D and racial disparity in albuminuria: NHANES 2001-2006. Am J Hypertens. 2011;24(10):1114-1120.
141. Inaguma D, Nagaya H, Hara K, et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol. 2008;12(2):126-131.
142. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76(9):977-983.
143. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-Hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol. 2009;20(12):2631-2639.
144. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88-95.
145. Wang AY, Lam CW, Sanderson JE, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr. 2008;87(6):1631-1638.
146. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007;18(2):613-620.
147. Drechsler C, Verduijn M, Pilz S, et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD Study. Nephrol Dial Transplant. 2011;26(3):1024-1032.
148. Ambrus C, Almasi C, Berta K, et al. Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol. 2011;43(2):475-482.
149. de Boer IH, Katz R, Chonchol M, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2011;6(9):2141-2149.
150. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20(8):1805-1812.
151. Navaneethan SD, Schold JD, Arrigain S, et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis. 2011;58(4):536-543.
152. Nigwekar SU, Bhan I, Thadhani R. Nutritional vitamin D in dialysis patients: what to D-iscern? Nephrol Dial Transplant. 2011;26(3):764-766.
153. Stanbury SW. Azotaemic renal osteodystrophy. Br Med Bull. 1957;13(1):57-60.
154. Dent CE, Harper CM, Philpot GR. The treatment of renal-glomerular osteodystrophy. Q J Med. 1961;30:1-31.
155. Berl T, Berns AS, Hufer WE, et al. 1,25 Dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med. 1978;88(6):774-780.
156. Malluche HH, Ritz E, Werner E, Meyer-Sabellek WA. Long-term administration of vitamin D steroles in incipient and advanced renal failure: effect on bone histology. Clin Nephrol. 1978;10(6):219-228.
157. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50(1):59-68.
158. 2) in stage 5 chronic kidney disease patients. J Ren Nutr. 2008;18(4):375-382.
159. Bouchard J, Ouimet D, Vallee M, Leblanc M, Pichette V. Effect of vitamin D supplementation on calcidiol and parathyroid hormone levels. Perit Dial Int. 2008;28(5):565.
160. Bucharles S, Barberato SH, Stinghen AE, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr. 2012;22(2):284-291.
161. DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton). 2006;11(6):555-559.
162. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009;24(12):3799-3805.
163. Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 2011;80(8): 851-860.
164. Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5(5):905-911.
165. Shah N, Bernardini J, Piraino B. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int. 2005;25(4):362-366.
166. Tokmak F, Quack I, Schieren G, et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant. 2008;23(12):4016-4020.
167. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36-43.
168. 3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008;14(1):10-17.
169. Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H. Effect of depot oral cholecalciferol treatment on secondary hyper-parathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail. 2008;30(4):407-410.
170. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis. 2012;59(1):58-66.
171. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):299-306.
172. Oksa A, Spustova V, Krivosikova Z, et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res. 2008;31(5):322-329.
173. Massry S. K/DOQI guidelines released on bone metabolism and disease in CKD. Nephrol News Issues. 2003;17(12):38-41, 44.
174. 3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387-5391.